Edwards Lifesciences (EW) Non Operating Income (2009 - 2026)

Edwards Lifesciences' Non Operating Income history runs 18 years deep, the most recent figure standing at -$18.6 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 147.57% year-over-year to -$18.6 million in Q1 2026; TTM through Mar 2026 was -$51.7 million, a 126.65% decrease from a year earlier, with the FY2025 full-year figure at $8.7 million, down 94.86% from the prior year.
• Non Operating Income climbed to -$18.6 million in Q1 2026 per EW's latest filing, from -$60.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $113.1 million in Q4 2024 and bottomed at -$60.7 million in Q4 2025.
• The 5-year median for Non Operating Income is $13.7 million (2022), against an average of $14.7 million.
• Across the five-year window, Non Operating Income surged 716.67% in 2022 and tumbled 162.86% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $13.7 million in 2022, then soared by 48.91% to $20.4 million in 2023, then jumped by 454.41% to $113.1 million in 2024, then tumbled by 153.67% to -$60.7 million in 2025, then jumped by 69.36% to -$18.6 million in 2026.
• Per Business Quant, the three latest EW Non Operating Income figures stand at -$18.6 million (Q1 2026), -$60.7 million (Q4 2025), and $38.6 million (Q3 2025).